信达生物(01801.HK)与奥赛康药业就肺癌靶向药奥壹新达成战略合作

阿斯达克财经10-08

信达生物(01801.HK) 与奥赛康药业(002755.SZ) 近日签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向药物“利厄替尼片”(商品名称：奥壹新)达成独家商业化合作。奥赛康药业将作为合作产品的上市许可持有人，负责合作产品的商业化生产及供货，并根据合作协议向信达生物支付销售推广服务费。信达生物取得合作产品在中国大陆地区的独家推广销售权，将按合作协议约定向...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2473464387?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190319114710011_s.jpg","is_english":false,"pubTime":"2024-10-08 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473464387","market":"other","top_or_hot":-1,"title":"信达生物(01801.HK)与奥赛康药业就肺癌靶向药奥壹新达成战略合作","media":"阿斯达克财经","content":"<div>\n<p>信达生物(01801.HK) 与奥赛康药业(002755.SZ) 近日签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向药物“利厄替尼片”(商品名称：奥壹新)达成独家商业化合作。奥赛康药业将作为合作产品的上市许可持有人，负责合作产品的商业化生产及供货，并根据合作协议向信达生物支付销售推广服务费。信达生物取得合作产品在中国大陆地区的独家推广销售权，将按合作协议约定向...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1386644/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>信达生物(01801.HK)与奥赛康药业就肺癌靶向药奥壹新达成战略合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n信达生物(01801.HK)与奥赛康药业就肺癌靶向药奥壹新达成战略合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 10:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1386644/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>信达生物(01801.HK) 与奥赛康药业(002755.SZ) 近日签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向药物“利厄替尼片”(商品名称：奥壹新)达成独家商业化合作。奥赛康药业将作为合作产品的上市许可持有人，负责合作产品的商业化生产及供货，并根据合作协议向信达生物支付销售推广服务费。信达生物取得合作产品在中国大陆地区的独家推广销售权，将按合作协议约定向...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1386644/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1386644/latest-news/AAFN","article_id":"2473464387","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190319114710011_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473464387","pubTimestamp":1728355920,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"信达生物与奥赛康药业近日签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂靶向药物“利厄替尼片”达成独家商业化合作。信达生物集团创始人、董事长兼首席执行官俞德超表示，与奥赛康在奥壹新的合作有望为广大的EGFR突变肺癌患者提供一个创新靶向药物，同时将进一步提升信达生物在肿瘤治疗领域的领先地位。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0239":"医药制造","BK1161":"生物科技","BK1589":"北水核心资产","01801":"信达生物","002755":"奥赛康","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0028":"国家队"},"translate_title":"Innovent Biologics (01801. HK) and Osaikang Pharmaceuticals have reached a strategic cooperation on lung cancer targeted drug Aoyixin","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002755":1,"01801":1},"content_text":"信达生物(01801.HK) 与奥赛康药业(002755.SZ) 近日签订合作协议，双方将就第三代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)靶向药物“利厄替尼片”(商品名称：奥壹新)达成独家商业化合作。奥赛康药业将作为合作产品的上市许可持有人，负责合作产品的商业化生产及供货，并根据合作协议向信达生物支付销售推广服务费。信达生物取得合作产品在中国大陆地区的独家推广销售权，将按合作协议约定向奥赛康药业支付首付款、注册里程碑和销售里程碑款项。国家药监局目前正在审评审批利厄替尼片的两项适应症新药上市申请，分别为既往经EGFR酪氨酸激酶抑制剂(TKI)治疗时或治疗后出现疾病进展，并且经检测确认存在EGFR T790M突变阳性，或原发性EGFR T790M突变阳性的局部晚期或转移性非小细胞肺癌成人患者的治疗；以及具有表皮生长因子受体(EGFR)外显子19缺失，或外显子21置换突变的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。信达生物集团创始人、董事长兼首席执行官俞德超表示，与奥赛康在奥壹新的合作有望为广大的EGFR突变肺癌患者提供一个创新靶向药物，同时将进一步提升信达生物在肿瘤治疗领域的领先地位。(gc/w)(港股报价延迟最少十五分钟。沽空资料截至 2024-10-07 16:25。) (A股报价延迟最少十五分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473464387"}